These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 20662899)

  • 41. Flow cytometry and targeted immune transcriptomics identify distinct profiles in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors with or without interferon-α.
    Alves R; McArdle SEB; Vadakekolathu J; Gonçalves AC; Freitas-Tavares P; Pereira A; Almeida AM; Sarmento-Ribeiro AB; Rutella S
    J Transl Med; 2020 Jan; 18(1):2. PubMed ID: 31900171
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia.
    Sopper S; Mustjoki S; White D; Hughes T; Valent P; Burchert A; Gjertsen BT; Gastl G; Baldauf M; Trajanoski Z; Giles F; Hochhaus A; Ernst T; Schenk T; Janssen JJ; Ossenkoppele GJ; Porkka K; Wolf D
    J Clin Oncol; 2017 Jan; 35(2):175-184. PubMed ID: 28056193
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile.
    Kreutzman A; Rohon P; Faber E; Indrak K; Juvonen V; Kairisto V; Voglová J; Sinisalo M; Flochová E; Vakkila J; Arstila P; Porkka K; Mustjoki S
    PLoS One; 2011; 6(8):e23022. PubMed ID: 21857985
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Increased Expression of TIGIT/CD57 in Peripheral Blood/Bone Marrow NK Cells in Patients with Chronic Myeloid Leukemia.
    Yao D; Xu L; Liu L; Zeng X; Zhong J; Lai J; Zheng R; Jin Z; Chen S; Zha X; Huang X; Lu Y
    Biomed Res Int; 2020; 2020():9531549. PubMed ID: 33102599
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy.
    Mustjoki S; Auvinen K; Kreutzman A; Rousselot P; Hernesniemi S; Melo T; Lahesmaa-Korpinen AM; Hautaniemi S; Bouchet S; Molimard M; Smykla R; Lee FY; Vakkila J; Jalkanen S; Salmi M; Porkka K
    Leukemia; 2013 Apr; 27(4):914-24. PubMed ID: 23192016
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biological therapy and the immune system in patients with chronic myeloid leukemia.
    Rohon P
    Int J Hematol; 2012 Jul; 96(1):1-9. PubMed ID: 22661045
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens.
    Fei F; Yu Y; Schmitt A; Rojewski MT; Chen B; Greiner J; Götz M; Guillaume P; Döhner H; Bunjes D; Schmitt M
    Exp Hematol; 2008 Oct; 36(10):1297-308. PubMed ID: 18619726
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli.
    Söderlund S; Christiansson L; Persson I; Hjorth-Hansen H; Richter J; Simonsson B; Mustjoki S; Olsson-Strömberg U; Loskog A
    Leuk Res; 2016 Nov; 50():95-103. PubMed ID: 27710869
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dasatinib suppresses in vitro natural killer cell cytotoxicity.
    Blake SJ; Bruce Lyons A; Fraser CK; Hayball JD; Hughes TP
    Blood; 2008 Apr; 111(8):4415-6. PubMed ID: 18398058
    [No Abstract]   [Full Text] [Related]  

  • 50. Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia.
    Harrington P; Dillon R; Radia D; Rousselot P; McLornan DP; Ong M; Green A; Verde A; Hussain F; Raj K; Kordasti S; Harrison C; De Lavallade H
    Haematologica; 2023 Jun; 108(6):1555-1566. PubMed ID: 36700403
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comprehensive analysis of the immune pattern of T cell subsets in chronic myeloid leukemia before and after TKI treatment.
    Yao D; Lai J; Lu Y; Zhong J; Zha X; Huang X; Liu L; Zeng X; Chen S; Weng J; Du X; Li Y; Xu L
    Front Immunol; 2023; 14():1078118. PubMed ID: 36742315
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The tyrosine kinase inhibitor dasatinib reduces the growth of intracellular Mycobacterium tuberculosis despite impairing T-cell function.
    Wehrstedt S; Kubis J; Zimmermann A; Bruns H; Mayer D; Grieshober M; Stenger S
    Eur J Immunol; 2018 Nov; 48(11):1892-1903. PubMed ID: 30242834
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dasatinib-induced anti-leukemia cellular immunity through a novel subset of CD57 positive helper/cytotoxic CD4 T cells in chronic myelogenous leukemia patients.
    Watanabe N; Takaku T; Takeda K; Shirane S; Toyota T; Koike M; Noguchi M; Hirano T; Fujiwara H; Komatsu N
    Int J Hematol; 2018 Dec; 108(6):588-597. PubMed ID: 30151740
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cytotoxic cell populations developed during treatment with tyrosine kinase inhibitors protect autologous CD4+ T cells from HIV-1 infection.
    Vigón L; Rodríguez-Mora S; Luna A; Sandonís V; Mateos E; Bautista G; Steegmann JL; Climent N; Plana M; Pérez-Romero P; de Ory F; Alcamí J; García-Gutierrez V; Planelles V; López-Huertas MR; Coiras M
    Biochem Pharmacol; 2020 Dec; 182():114203. PubMed ID: 32828803
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Simultaneous occurrence of chronic myeloid leukemia and chronic lymphocytic leukemia: report of an unusual case.
    Rahman K; George S; Mangal S; Mehta A
    Indian J Pathol Microbiol; 2013; 56(4):453-6. PubMed ID: 24441247
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance.
    Levitzki A
    Annu Rev Pharmacol Toxicol; 2013; 53():161-85. PubMed ID: 23043437
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Therapeutic immune monitoring of CD4
    Lu Z; Xu N; Zhou X; Gao G; Li L; Huang J; Li Y; Lu Q; He B; Pan C; Liu X
    Oncol Lett; 2017 Aug; 14(2):1363-1372. PubMed ID: 28808483
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Robust in vivo differentiation of t(8;21)-positive acute myeloid leukemia blasts to neutrophilic granulocytes induced by treatment with dasatinib.
    Chevalier N; Solari ML; Becker H; Pantic M; Gärtner F; Maul-Pavicic A; Hübner J; Wäsch R; Schmitt-Gräff A; Lübbert M
    Leukemia; 2010 Oct; 24(10):1779-81. PubMed ID: 20811401
    [No Abstract]   [Full Text] [Related]  

  • 59. Abnormal immune function of MDSC and NK cells from chronic phase CML patients restores with tyrosine kinase inhibitors.
    Hong Y; Wen R; Wu G; Li S; Liu W; Chen Z; Yang Z
    Int Immunopharmacol; 2022 Aug; 109():108821. PubMed ID: 35526383
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors.
    Powers JJ; Dubovsky JA; Epling-Burnette PK; Moscinski L; Zhang L; Mustjoki S; Sotomayor EM; Pinilla-Ibarz JA
    Leuk Lymphoma; 2011 Apr; 52(4):668-79. PubMed ID: 21271862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.